Global RNAi Therapeutics Market Report 2023-2030, with Competitor Analysis for Alnylam Pharmaceuticals, QIAGEN, Olix Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals & Benitec Biopharma

News provided by

Jan 18, 2024, 06:15 ET

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ResearchAndMarkets.com's offering.

The global RNAi therapeutics market was valued at USD 11.20 billion in 2022 and is expected to reach USD 20.23 billion in 2030, with a CAGR of a 7.69% during the forecast period 2023-2030. The study on RNAi therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

The report on RNAi therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNAi therapeutics market over the period of 2021-2030. The Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNAi therapeutics market over the period of 2021-2030. The report's Growth Matrix provides insight into the investment areas that existing or new market players can consider.

Key Market Insights

Intensive R&D efforts are propelling advances in RNAi therapeutics, which promise to revolutionize the approach to treating chronic diseases.
Collaboration between drug distribution enterprises and Contract Research Organizations (CROs) continues to be a pivotal growth factor in the industry.
Innovative progress in RNAi delivery mechanisms is anticipated to expand the range of therapeutic indications, offering lucrative market opportunities.

In contrast to the drivers, one of the main restraints highlighted in the market analysis is the complexity involved in the delivery mechanisms of RNAi therapeutics, which can pose challenges to market growth.

Report Segmentation

The global RNAi therapeutics market is segmented on the basis of type, application, route of administration, and end user.

The Global RNAi Therapeutics Market by Type

Small interfering RNA (siRNA)
MicroRNA (miRNA)

The Global RNAi Therapeutics Market by Application

Genetic Disorders
Oncology
Neurodegenerative Disorders
Infectious Diseases
Renal Diseases
Others

The Global RNAi Therapeutics Market by Route of Administration

Intradermal Injections
Pulmonary Delivery
Intravenous Injections

The Global RNAi Therapeutics Market by End User

Diagnostic Laboratories
Research and Academic Laboratories
Hospitals

Company Profiles

Alnylam Pharmaceuticals
QIAGEN
Olix Pharmaceuticals
Arbutus Biopharma
Silence Therapeutics
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Quark Software
Phio Pharmaceuticals
Benitec Biopharma

What does this Report Deliver?

Comprehensive analysis of the global as well as regional markets of the RNAi therapeutics market.
Complete coverage of all the segments in the RNAi therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
Comprehensive analysis of the companies operating in the global RNAi therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

For more information about this report visit https://www.researchandmarkets.com/r/x9tyal

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets